This invention describes novel adjuvant compositions and formulations withexcellent stability at refrigerated and room temperatures and up to and about37°C that can be produced at remarkably low costs. This inventiondescribesnovel vaccine compositions and formulations to treat and prevent urinary tractinfections caused by gram-negative bacteria including Escherichia coli andmulti-drugresistant E. coli. This invention also describes methods of administration ofsaid novel vaccine compositions and formulations and methods of treatment toprevent and treat urinary tract infections caused by gram-negative bacteriaincluding E. coli and multi-drug resistant E. coli.
